$599

GSK’s Daprodustat Approved by FDA

FDA announced the approval of GSK’s daprodustat as Jesduvroq for the treatment of CKD anemia in dialysis-dependent (DD) patients. The approval comes after multiple CRLs for Fibrogen/AZ’s roxadustat and Akebia/Otsuka’s vadadustat. The Jesduvroq label has not yet been observed. Below, FENIX provides brief thoughts on the Jesduvroq approval.

This content is for Read Less members only.
Register
Already a member? Log in here